Skip to content

Acute Coronary Syndrome CardioFlux TM Study (ACCMED)

The Acute Coronary Syndrome Accelerated CardioFlux TM Magnetocardiography-based Early Disposition Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04739267
Acronym
MAGNETO
Enrollment
390
Registered
2021-02-04
Start date
2021-01-27
Completion date
2023-03-03
Last updated
2023-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Injuries

Keywords

Ischemia, Cardiovascular Disease, MCG, CardioFlux

Brief summary

Approximately 16.5 million people suffer from coronary artery disease (CAD) and about 10 million present each year to emergency departments with symptoms like chest pain and shortness of breath, commonly suggestive of acute coronary syndrome (ACS). To clinically assess ACS risk in these patients, there are typically 2-6 hours of emergency room evaluation, followed by 6-42 hours of an observation period prior to discharge. The clinical pathway includes: 1) 1-3 ECG's; 2) serial troponins (1 and 3 hours vs 1 and 6 hours); and 3) other pertinent diagnostic information, including but not limited to echocardiography, stress testing and/or CT Angiography. Patients who are evaluated, have presented with a low risk for ACS, and maintain negative diagnostic results can potentially be discharged within 6 hours. However, 20%-40% of patients who fall into indeterminate diagnostic categories will require longer observation periods or admission of 12-48 hours which result in the use of expensive imaging and provocative testing, such as stress testing. The purpose of ACCMED is to measure the efficacy of Magnetocardiography (MCG) as a diagnostic tool to rule-in/rule-out myocardial ischemia in patients with suspicion of an acute coronary syndrome who have a HEART Score \> 2 and to allow safe and timely disposition of the patient to an appropriate level of care.

Interventions

Not an intervention

Sponsors

Genetesis Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. ≥ 18 years of age at the time of enrollment. 2. Patient presenting acutely with signs and symptoms suggestive of ACS. 3. Informed Consent Form signed by subject or LAR. 4. HEART Score of \>2. 5. Patient consented within 4 hours of the beginning of the clinical assessment (exclusive of any screening examination) for suspected ACS by an appropriately credentialed clinician.

Exclusion criteria

1. \< 18 years of age. 2. STEMI. 3. Unable to fit into device. 4. Non-ambulatory patients. 5. Positive response on MCG metal checklist. 6. Deemed hemodynamically unstable by treating physician, regardless of cause. 7. Unable to lie supine for up to 5 minutes. 8. Poor candidate for follow-up (e.g., no access to phone). 9. Prisoners. 10. Repeat participants.

Design outcomes

Primary

MeasureTime frameDescription
To prove that MCG can accurately diagnose myocardial ischemia1 yearDemonstrate the following: 1. MCG has a clinically acceptable sensitivity and specificity for the detection of myocardial ischemia. This will be compared to the Gold Standard of index revascularization, ≥70% stenosis in any coronary artery as determined by invasive coronary angiography, or 30-day MACE. 2. MCG is non-inferior to noninvasive downstream testing (DS) for the identification of patients with myocardial ischemia. 3. MCG is non-inferior to noninvasive downstream testing (DS) for appropriate referral of patients to invasive coronary angiography with decision to refer the patient to the coronary catheterization laboratory as the Gold Standard.

Secondary

MeasureTime frame
To demonstrate that MCG provides value to the traditional HEART score for risk stratification of patients with suspected ACS.1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026